^
    Back
    Association details:
    Biomarker:PDGFRA D842V
    Cancer:Gastrointestinal Stromal Tumor
    Drug:Focus V (anlotinib) (Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    Oncologist
    Title:

    Activity of Anlotinib in the Second-Line Therapy of Metastatic Gastrointestinal Stromal Tumors: A Prospective, Multicenter, In Vitro Study

    Published date:
    02/13/2023
    Excerpt:
    In addition, 1 patient with PDGFRA D842V mutation got 8.5 months PFS and no tumor progression happened and 3 patients with SDHB-deficient GIST had average of 16 months PFS....In summary, anlotinib showed moderate antitumor activity in drug-resistant GIST cell lines in vitro, and acceptable PFS and good tolerance were obtained in this prospective study.
    DOI:
    10.1093/oncolo/oyac271